Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bioqual Inc. stock logo
BIOQ
Bioqual
$33.00
$32.66
$32.50
▼
$43.55
$29.37M-0.261 shsN/A
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
$3.19
$1.62
▼
$10.97
$6K0.7271,922 shs3,245 shs
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
$18.38
+4.3%		$15.69
$8.20
▼
$23.40
$74.26M-1862.2651,450 shs3,020 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bioqual Inc. stock logo
BIOQ
Bioqual
0.00%0.00%+1.54%+1.54%-15.38%
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
0.00%0.00%0.00%0.00%+100.00%
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
-3.40%+6.40%-4.55%+26.11%+145,602.48%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bioqual Inc. stock logo
BIOQ
Bioqual
$33.00
$32.66
$32.50
▼
$43.55
$29.37M-0.261 shsN/A
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
$3.19
$1.62
▼
$10.97
$6K0.7271,922 shs3,245 shs
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
$18.38
+4.3%		$15.69
$8.20
▼
$23.40
$74.26M-1862.2651,450 shs3,020 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bioqual Inc. stock logo
BIOQ
Bioqual
0.00%0.00%+1.54%+1.54%-15.38%
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
0.00%0.00%0.00%0.00%+100.00%
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
-3.40%+6.40%-4.55%+26.11%+145,602.48%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bioqual Inc. stock logo
BIOQ
Bioqual
0.00
N/AN/AN/A
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
0.00
N/AN/AN/A
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
2.75
Moderate Buy$41.50133.54% Upside

Current Analyst Ratings Breakdown

Latest BIOQ, CBLI, and ELOX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/24/2026
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$43.00
8/20/2026
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
Lucid Cap Mkts logo
Lucid Cap Mkts
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/14/2026
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageSell (D)
7/22/2026
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
Lifesci Capital logo
Lifesci Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$40.00
7/20/2026
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$43.00
7/20/2026
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$43.00
(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bioqual Inc. stock logo
BIOQ
Bioqual
$48.87M0.60$1.48 per share22.33$40.42 per share0.82
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
$260K0.00N/AN/A$0.87 per share0.00
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
$6.36M11.29N/AN/A($85.17) per share-0.21
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bioqual Inc. stock logo
BIOQ
Bioqual
-$1.05M-$1.08N/AN/AN/A-2.27%-2.69%-1.50%N/A
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
-$2.40MN/AN/AN/AN/AN/A-32.84%-31.29%N/A
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
-$5.99M-$1.54N/AN/AN/AN/AN/AN/AN/A

Latest BIOQ, CBLI, and ELOX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
N/A-$0.66N/A-$0.66N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bioqual Inc. stock logo
BIOQ
Bioqual
N/AN/AN/AN/AN/A
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
N/AN/AN/AN/AN/A
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bioqual Inc. stock logo
BIOQ
Bioqual
N/A
4.01
4.01
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
N/A
45.93
45.93
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
N/A
3.74
3.74

Institutional Ownership

CompanyInstitutional Ownership
Bioqual Inc. stock logo
BIOQ
Bioqual
N/A
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
5.09%
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
2.90%

Insider Ownership

CompanyInsider Ownership
Bioqual Inc. stock logo
BIOQ
Bioqual
39.24%
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
1.03%
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
25.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bioqual Inc. stock logo
BIOQ
Bioqual
114890,000543,000Not Optionable
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
415.48 millionN/ANot Optionable
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
74.04 million2.99 millionN/A

Recent News About These Companies

Financial Contrast: Eloxx Pharmaceuticals (ELOX) vs. Its Rivals
September 17 at 2:46 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31028161
Critical Survey: Eloxx Pharmaceuticals (ELOX) versus Its Peers
September 14 at 4:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31022758
Eloxx Pharmaceuticals, Inc.: Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
September 11, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69556187-eloxx-pharmaceuticals-inc-eloxx-pharmaceuticals-announces-first-patients-dosed-in-phase-2b-exact-study-of-exaluren-in-nonsense-mutation-alport-synd-008.htm
Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
September 11, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/eloxx-pharmaceuticals-announces-first-patients-dosed-in-phase-2b-exact-study-of-exaluren-in-nonsense-mutation-alport-syndrome-302876003.html
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/eloxx-pharmaceuticals-reports-second-quarter-2026-financial-results-and-provides-business-update-302849070.html
Eloxx’s EXACT Study Puts Exaluren in Focus for Rare Kidney Disease Investors
July 1, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/eloxxs-exact-study-puts-exaluren-in-focus-for-rare-kidney-disease-investors?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bioqual stock logo

Bioqual OTCMKTS:BIOQ

$33.00 0.00 (0.00%)
As of 09/11/2026

Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is based in Rockville, Maryland.

Cleveland BioLabs stock logo

Cleveland BioLabs NASDAQ:CBLI

Cytocom, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel small molecule immunotherapies. Its product applies to autoimmune, inflammatory, infectious diseases and cancers. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.

Eloxx Pharmaceuticals stock logo

Eloxx Pharmaceuticals NASDAQ:ELOX

$18.38 +0.75 (+4.25%)
As of 10:47 AM Eastern

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company's lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas